Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
Roy M FleischmannDésirée Mfm van der HeijdeVibeke StrandTatsuya AtsumiIain B McInnesTsutomu TakeuchiPeter C TaylorMarguerite BracherDavid BrooksJohn DaviesChristopher GoodeAnubha GuptaSumanta MukherjeeCiara O'SheaDidier SaurignyLorrie A SchifanoCelia SheltonJulia E SmithMillie WangReena WangSarah WattsMichael E WeinblattPublished in: Annals of the rheumatic diseases (2023)
NCT03980483, NCT03970837.
Keyphrases
- rheumatoid arthritis
- magnetic resonance
- disease activity
- double blind
- clinical trial
- contrast enhanced
- placebo controlled
- rheumatoid arthritis patients
- open label
- interstitial lung disease
- ankylosing spondylitis
- study protocol
- magnetic resonance imaging
- randomized controlled trial
- computed tomography
- cerebrospinal fluid